What does Acalabrutinib treat?

Acalabrutinib (Acalabrutinib) is a targeted drug used to treat B cell malignant tumors. It is a type of BTK (brutinib) inhibitor. Its main indications include chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), both of which are B cell-related hematological malignancies.

1.Chronic lymphocytic leukemia (CLL): This is a chronic form of leukemia that mainly involves lymphocytes. Patients will have abnormally proliferated BB cells in their bone marrow, lymphoid tissues and blood, leading to immune system dysfunction. By inhibiting BTK, acotinib blocks the abnormal activity of B cells, thereby helping to control the disease and delay the progression of the disease.

2.Small lymphocytic lymphoma (SLL): This is a B cell malignancy similar to CLL, but SLL usually presents with swollen lymph nodes and a relatively small increase in lymphocytes in the blood. Acotinib also shows certain effects in the treatment of SLL by inhibiting BTK and interfering with B cell signaling pathways.

Acotinib's mechanism of action involves the selective inhibition of BTK, a key tyrosine kinase in the B cell signaling pathway. By inhibiting BTK, acotinib blocks the abnormal activation of B cells, thereby slowing or stopping the growth and spread of cancer cells.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.